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Abstract
Urease plays a significant role in the pathogenesis of urolithiasis pyelonephritis, urinary catheter
encrustation, hepatic coma, hepatic encephalopathy, and peptic acid duodenal ulcers. Salvinia
molesta was explored to identify new bioactive compounds with particular emphasis on urease
inhibitors.

A

new

glucopyranose

derivative

6′-O-(3,4-dihydroxybenzoyl)-4′-O-(4-

hydroxybenzoyl)-α/β-D-glucopyranoside (1) was isolated from Salvinia molesta and its structure
assigned using a combination of NMR (1D and 2D), mass spectrometry (ESI-QTOF), and IR
spectroscopy. This novel glycoside was evaluated for antioxidant activity (using DPPH,
superoxide anion radical scavenging, oxidative burst, and Fe+2 chelation assays), anti-glycation
behaviour, anticancer activity, carbonic anhydrase inhibition, phosphodiesterase inhibition, and
urease inhibition. Glycoside 1 demonstrated promising antioxidant potential with IC50 values of
48.2±0.3, 60.3±0.6, and 42.1±1.8 µM against DPPH, superoxide radical, and oxidative burst,
respectively. Its IC50 in the Jack bean urease inhibition assay was 99.1±0.8 µM. The mechanismbased kinetic studies presented that compound 1 is a mixed-type inhibitor of urease with a Ki value
of 91.8±0.1 µM. Finally, molecular dynamic simulations exploring the binding mode of compound
1 with urease, provided quantitative agreement between estimated binding free energies and the
experimental results.

Keywords: Salvinia molesta, antioxidant, oxidative burst, urease inhibition, phosphodiesteraseI inhibition.

1. Introduction
Salvinia molesta D. S. Mitchell (S. molesta), also known as giant Salvinia, is a floating aquatic
fern of the Salviniaceae family, endogenous to south-eastern Brazil. It has spread worldwide in
recent decades, and has proved invasive in various aquatic habitats [1]. At present, it is believed
to be one of the most extensive aquatic plant species in environmental, economic, and social terms
[2]. In the wild, the broad masses of S. molesta provide an ideal habitat for mosquitoes and snails,
which transmit infectious diseases, such as dengue, malaria, and schistosomiasis, the second most
socioeconomically devastating parasitic disease after malaria [3]. It has rapidly joined the list of
“100 most noxious weeds” due to these harmful effects on human health and the environment,
exacerbated as it doubles in mass every 52 h [4]. However, it also serves as an ornamental plant
and has applications in mining phytoremediation, being able to sequester heavy metals and organic
material from contaminated water [5].
Based on the abundance and rapid growth, should S. molesta harbour biomedically relevant
phytoconstituents, they would be extremely readily available. Moreover, characterization of its
secondary metabolite profile could identify mechanisms for managing its aggressive growth. A
variety of phytochemicals such as phenols and their glycosides, steroids, xanthoproteins,
coumarins, tannins, and terpenes have been isolated in this plant. Abietane diterpene, with its
ferruginol-menthol skeleton, and salviniside I and salviniside II are among the novel constituents
previously isolated. Some other trace constituents included aromatic acid derivatives, fatty acids,
acyclic sesquiterpenes, jasmonate, paeoniflorin, and pikuroside [6, 7]. Some of these compounds
are potent antioxidants, and anticancer candidates [8].

Highly reactive free radicals produced in living systems in the form of reactive oxygen species
(ROS) and reactive nitrogen species (RNS) have derived significant attention owing to their
involvement in ageing, as well as various disorders such as hepatic inflammation, fibrosis, cancer,
fibrosis, neurodegeneration, cardiac disorders, and cancer. The disturbed redox homeostasis as a
result of elevated levels of free radicals is termed as oxidative stress. The compounds capable of
interacting with free radicals to alleviate oxidative stress, also known as antioxidants, have pivotal
significance in treating and preventing various disorders [9, 10].
Urease, a urea amidohydrolase (EC 3.3 1.5) found in fungi, bacteria and plants, catalyzes the
hydrolysis of urea to ammonia and carbon dioxide [11], supplying nitrogen for microorganism
growth [12]. Elevated bacterial ureolytic activity raises the amount of ammonia in soil, decreasing
the burden on fertilizer use. In the body, it facilitates the survival of Helicobacter pylori in the
stomach's low pH environment and thus is involved in the pathogenesis of peptic and gastric ulcers.
Urease is also involved in infectious urolithiasis caused by the urease producing bacteria Yersinia
enterocolitica and Proteus mirabilis. Secreted urease also exacerbate arthritis and acute
pyelonephritis [13, 14].
When overrepresented in the soil due to high bacteria levels, urease-related toxicity, leading to
high levels of ammonia and CO2, can harm many crop plants. However, moderate levels play an
essential role in nitrogen metabolism during seed germination, and ensure symbiotic soil microbes
obtain the nitrogen, necessary for their growth [15, 16]. Urease regulation is extremely important
and plants have developed a series of endogenous control mechanisms, making bioprospecting for
potent urease inhibitors fruitful [17]. Although a variety of synthetic compounds such as triazoles,
thiazoles, keto acids, isocoumarins, and thiobarbituric acids have the potential to inhibit urease,

the discovery of new urease inhibitors from plants has broader potential to be exploited [18-20].
Extracts of S. molesta have shown this activity. This study aims to identify them.

2. Experimental
2.1. Plant collection and authentication
S. molesta D. S. Mitchell whole plant was collected from the freshwater Haliji Lake, District Thatta,
Sindh, Pakistan, in the first quarter of 2003. The taxonomic analysis was by
Prof. Dr. Surraya Khatoon, at the Department of Botany (University of Karachi, Karachi, Pakistan)
and a voucher specimen (No. 85912) was submitted to the herbarium of the university.
2.2. Extraction and fractionation
The shade-dried whole plant of S. molesta (20 kg) was macerated in 80% aqueous methanol
(MeOH) (50 L) and stored in the dark for one week while occasionally shaken. The extract was
filtered, and the process repeated two times with the residue. The filtrates were evaporated under
reduced pressure on a rotary evaporator, and combined to provide 800 g of crude extract. After
adding water, the extract was sequentially extracted with n-hexane (220 g dry weight), diethyl
ether (180 g dry weight), ethyl acetate (25 g dry weight), and butanol (20 g dry weight), leaving a
residual aqueous-soluble fraction (355 g dry weight).
2.3. Compound isolation and identification
A Diaion HP-20 column was used to fractionate the butanol extract with an H2O-MeOH gradient
solvent system. The fraction eluted with a 1:1 H2O-MeOH solvent mixture was then subjected to
polyamide chromatography with a CHCl3-MeOH gradient solvent system, starting with 100%
CHCl3 with 10% step increments in the methanol content, providing eleven fractions (P1-P11)
obtained from the various extractions. The fractions with the same TLC profile (P5-P9) were

combined (10 g) and fractionated using the Sephadex LH-20 column using a gradient elution with
an H2O-MeOH solvent system to afford four fractions. The final purification was performed on a
reverse phase recycling HPLC with H2O-MeOH (1:1) and an L-80 column providing a new
compound 1 (102 mg) and two unresolved fractions A and B. These fractions were separately
resolved using an H-80 column with H2O-MeOH (1:1) solvent resulting in the isolation of four
known compounds 2-5 [6]. The structure elucidation was performed using UV (Hitachi UV-3200),
IR (JASCO 302-A), NMR (Bruker AMX-500 with tetramethylsilane as internal standard), and
HRMS (ESI-QTOF, Applied Biosystems).
2.4. Biological activity
2.4.1. Antioxidant activity
2.4.1.1. DPPH assay
DPPH (di(phenyl)-(2,4,6-trinitrophenyl)iminoazanium) assay was carried out on a 96-well plate.
The dilutions of test compound or standard (gallic acid) were prepared in DMSO, while 0.3 mM
solution of DPPH was prepared in ethanol. The test compound or standard (5 μL) and DPPH (95
μL) were added to the wells. The plate contents were manually swirled for around 1 min and then
incubated in the dark for 30 min at 37˚C. The optical density was measured at 515 nm using a
microplate reader (SpectraMax M5, Molecular Devices, CA, USA). DMSO was used as a control,
and percentage radical scavenging activity (%RSA) was measured using the following relation
[7]:
%RSA = 100-(As /Ac)×100
As and Ac are absorbances of sample and control, respectively. The experiment was repeated in
triplicate, the mean and standard error was calculated, and IC50 determined.

2.4.1.2. Superoxide anion radical assay
Phosphate buffer (0.1 M, pH 7.4) was used to prepare 0.2 mM β-nicotinamide adenine dinucleotide
(NADH), 0.081 mM nitro blue tetrazolium (NBT) and 0.008 mM phenazine methosulphate (PMS).
The stock solutions and dilutions of test compound or standard (quercetin) were prepared in
DMSO. The analysis was carried out in a 96-well plate, and the reaction mixture contained 10 µL
test compound or standard, 90 µL of phosphate buffer, 40 µL NADH, and 40 µL NBT. The
reaction was started by adding 20 µL PMS and absorbance was measured at 560 nm 5 min [21].
Blank DMSO was used in place of the test compound as control, and the percentage of superoxide
anion inhibition was measured using the following relation:
Percentage of superoxide anion inhibition = 100-(As /Ac)×100
As and Ac are absorbances of sample and control, respectively. The experiment was repeated in
triplicate, the mean and standard error was calculated, and IC50 determined.
2.4.1.3. Oxidative burst assay
A luminol-enhanced chemiluminescence assay was conducted in 96-well plates, as described in
the literature [22]. Briefly, 25 µL of diluted whole blood HBSS++ (Hanks balanced salt solution
containing magnesium chloride and calcium chloride) was mixed with 25 µL of different
concentrations of 1 or the positive control (ibuprofen). HBSS++ was used as blank control, and the
plate was incubated (37°C for 15 min) in the thermostat chamber of the luminometer.
Subsequently, 25 µL of serum opsonized zymosan (SOZ) and 25 µL of intracellular reactive
oxygen species detecting probe (luminol) were added into each well, except blank wells
(containing only HBSS++). The ROS level was recorded in the luminometer in terms of relative

light units (RLU). The experiment was repeated in triplicate, the mean and standard error was
calculated, and IC50 determined.
2.4.1.4. Iron chelation assay
The Fe2+ ion chelating ability was determined according to the reported method with slight
modifications

[23].

The

test

compound's

dilutions

or

standard

disodium

salt

of

ethylenediaminetetraacetic acid (EDTA) were prepared in DMSO while other solutions were
prepared in distilled water. The test compound or standard (5 µL) was mixed with 0.3 mM FeCl2
(35 µL) and 0.5 mM ferrozine (60 µL). The reaction mixture was swirled and left at room
temperature for 10 min. The change in the optical density of the resulting mixture was measured
at 562 nm. Blank DMSO was used in place of the test compound as control, and the percentage of
ion chelation was measured using the following relation:
Percentage of Fe2+ ion chelation = 100-(As /Ac)×100
As and Ac are absorbances of sample and control, respectively. The experiment was repeated in
triplicate, the mean and standard error was calculated, and IC50 determined.
2.4.2. Anti-glycation assay
The selected concentrations of the test compound or standard rutin were prepared in DMSO.
Human serum albumin (HSA) (10 mg/mL) and fructose (0.5 M) solutions were prepared in
phosphate buffer (0.1 M, pH 7.4) containing sodium azide (3 mM). The assay was conducted in a
96-well plate with each well contained 50 µL HSA, 50 µL of fructose, 20 µL of the test compound,
and 80 µL of phosphate buffer. The plate was sealed and incubated for seven days at 37°C and
fluorescence were recorded at 330 and 440 nm as excitation and emission wavelengths,

respectively. The experiment was repeated in triplicate to calculate mean anti-glycation activity
[24].
2.4.3. MTT assay
The cells (HeLa or PC-3) were cultured in Minimum Essential Medium Eagle, supplemented with
5% of fetal bovine serum (FBS), 100 IU/mL penicillin, and 100 µg/mL streptomycin in 75 cm2
flask, and kept in 5% CO2 incubator at 37°C. The cells were harvested, and cell count was
maintained at 6×104 cells/mL using a hemocytometer. The cells were seeded (100 µL/well) in the
wells of 96-well plates and incubated overnight. The medium was removed, and 200 µL of fresh
medium was added with different test compounds or standard doxorubicin (positive control)
concentrations. After 48 h of incubation, 20 µL MTT (3-[4, 5-dimethylthiazole-2-yl]-2, 5diphenyl-tetrazolium bromide) (0.5 mg/ml) was added to each well and incubated for 4 h.
Subsequently, 100 µL of DMSO was added, and absorbance was measured at 570 nm to calculate
percentage inhibition. The blank medium was used in place of the test compound as the negative
control. Dose-response curves were plotted, and IC50 was calculated. The experiment was repeated
in triplicate, and the results were calculated as mean±standard error [25].
2.4.4. Phosphodiesterase-I inhibition assay
The reaction was performed in 33 mM tris-HC1 buffer (pH 8.8) with 30 mM magnesium acetate
and 0.000742 U/well of phosphodiesterase-I. bis-(p-nitropheny1) phosphate (0.33 mM) was used
as the substrate. EDTA was used as a positive control. After 30 min pre-incubation of the enzyme
and control or analyte, the reaction was initiated by adding the substrate. The enzyme activity was
monitored spectrophotometrically at 37C on a microtiter plate reader by following the rate
(change in O.D/min) of the release of p-nitrophenol from p-nitrophenyl phosphate at 410 nm. The
experiment was repeated in triplicate, and results were represented as mean±standard error [27].

2.4.5. Carbonic anhydrase-II inhibition assay
The experiment was performed in a buffer containing HEPES (4-(2-hydroxyethyl)-1piperazineethanesulfonic acid) and tris (20 mM, pH 7.4). Each well contained 140 µL of the
HEPES-tris buffer, 20 µL (0.1 mg/mL) of the freshly prepared aqueous solution of bovine
erythrocyte carbonic anhydrase II, and 20 µL of the analyte (selected concentrations in DMSO).
After 15 min of incubation, the reaction was initiated by the addition of 20 µL of the substrate (0.7
mM 4-nitrophenyl acetate in ethanol). The reaction rate was monitored by measuring absorbance
at 1 min intervals for 30 min at 400 nm. Acetazolamide was used as a standard, while DMSO was
used as blank control. Percentage inhibition was calculated, and the dose-response curve was
plotted to get IC50. The experiment was repeated in triplicate, and the results were represented as
mean±standard error [28].
2.4.6. Urease inhibition assay
A mixture of 25 μL of Jack bean urease (EC 3.5.1.5), 100 mM of urea, 55 μL of buffer at pH 6.8,
and 5 μL of different concentrations of test compound (0.5 to 0.00625 mM) were incubated for 15
min, at 30°C in 96-well plate. Each well was supplemented with 45 μL of pre-prepared phenol
reagent (1% w/v phenol and 0.005% w/v sodium nitroprusside in water), and 70 μL of alkali
reagent (0.5% w/v NaOH + 0.1% w/v NaOCl in water). Urease activity was determined through
the Weatherburn method [26]. The absorbance was recorded at 630 nm with a final volume of 200
μL. Thiourea was used as the standard. The results were formulated by using SoftMax Pro
(Molecular Devices, CA, USA), MS-Excel, and Ez-fit programs. Percent inhibition was calculated
from the optical density (OD) using the formula given below:
% Inhibition = 100 - (ODtest / ODcontrol) × 100

2.5. Docking and molecular dynamics simulation
The X-ray crystal structure of jack bean urease co-crystallized with acetohydroxamic acid was
retrieved from Protein Data Bank (PDB ID: 4H9M) [29]. UCSF Chimera (v. 1.14) was used to
remove co-crystallized water, 1,2-ethanediol, and acetohydroxamic acid from the structure. The
protein was then prepared for docking by adding hydrogens and Gasteiger charges, optimizing the
hydrogen bond network, and adjusting the protonation states of the histidine residues bound to the
nickel atoms. Moreover, the crystal structure of jack bean urease bears a bound phosphate and a
covalently modified cysteine residue (CME592), by β-mercaptoethanol at its active site; these are
not found in the free enzyme and are figments of the crystallization process, so the cysteine was
reverted during protein preparation. A cubic grid box with 25 Å length and center (19.18, -58.81,
-24.51) was marked around the active site bearing nickel atoms, and H-bond and/or metal-ligand
interaction constraints were also defined for the nickel ion during the docking simulations. During
docking, the hydrogen atoms of hydroxyl and thiol groups of the active site residues were allowed
to rotate to provide flexibility. The structure of compound 1 was constructed in Chem3D (v. 16.0)
and minimized using the MM2 force field and saved in the mol2 format. Docking simulations of
1 with the prepared protein were performed using AutoDock Tools, and the highest docking score
conformation was selected for further analysis. Molecular dynamics (MD) simulations were
performed using the AMBER 18 simulation package to analyze the stability of the overall complex
and the binding conformations available to compound 1. We employed the same MD simulation
protocol as described previously [30, 31]. Since, jack bean urease, a metalloprotein, contains
metals which are challenging for the AMBER default settings, the metal ions were parameterized
using the MTK++/MCPB facility [32] of AmberTools and modified accordingly for nickel radii.

The tleap sub-program in Amber was used to generate the topology and coordinate files. Extra
care was taken at the bi-nickel coordination site and bonds involving nickel atoms were defined.
Subsequently, the 1@urease complex was hydrated using a TIP3P water box (10 Å around the
solute). The overall solvated complex was then minimized, stepwise, employing weak harmonic
positional restraints on all atoms surrounding the bi-nickel coordination sphere. After both heating
and equilibration steps with weak positional restraints, a production run of 50 ns was performed at
standard temperature (300 K) and pressure (1 bar). The step period was set to 2 fs and snapshots
were stored every 4 ps. The CPPTRAJ program [33] of AMBER was utilized for trajectory analysis,
which included root-mean square deviation (RMSD), fluctuation (RMSF), and H-bond occupancy
analysis. The total binding free energy (ΔGtotal) of the complex was calculated using the MMGBSA (molecular mechanics-generalized Born surface area) method. The AMBER ff99SB
molecular mechanics (MM) force field [34] was utilized to estimate the energy contributions of
ligand, receptor and the complex using the following equations:
ΔEMM = ΔEint + ΔEele + ΔEvdW

(eq. 1)

ΔGsol = ΔGp + ΔGnp

(eq. 2)

ΔGtotal = ΔEMM + ΔGsol

(eq. 3)

ΔGbind = ΔEMM + ΔGsol – TΔS

(eq. 4)

Where ΔEMM is the sum of the internal energy (ΔEint), electrostatic energy (ΔEele), and van der
Waals energy (ΔEvdw, equation 1); the total solvation free energy (ΔGsol) is divided into polar (ΔGp)
and non-polar (ΔGnp) components (equation 2); and the total binding free energy (ΔGtotal) is the
sum of the internal energy and the total solvation free energy (equation 3); the binding energy,
ΔGbind, was evaluated by incorporating the entropic term, (TΔS), using equation 4. The MMGBSA approach has been successfully employed in binding free energy calculations in enzyme
inhibition studies [35].

Ki from urease enzyme inhibition assay was translated into ΔGbind-Ki with equation 5 for
comparison with ΔGbind from molecular dynamics simulation.
ΔGbind-Ki = − R T ln Ki

(eq. 5)

R is gas constant (1.987×10−3 kcal K−1 mol−1), and T is the temperature (300 K).
3. Results and discussion
The butanol extract of S. molesta was subjected to a series of chromatographic steps leading to the
isolation of a new compound (1) along with four known compounds (2-5).
3.1. Isolated compound from S. molesta.
Compound 1 was isolated from a sub-fraction of butanol extract by recycling HPLC with a watermethanol (1:1) solvent system using an H-80 column. The UV spectrum of compound 1 exhibited
absorption maxima at 333, 324 nm suggesting a p-hydroxy benzoyl moiety, and additional signals
at 259 and 195 nm, typical of an aromatic system with electron-donating substituents (REF). IR
displayed absorptions for -OH (3432 cm-1), aromatic C=C bond (2923 cm-1), and conjugated ester
(1682 cm-1) functionalities. The ESI-QTOF-MS suggested an [M+H]+ at m/z 475.1447, and
another signal at XXX.XXX for [M+K]+, corresponding to a molecular formula of C20H20O11
(calcd. 475.1006). The MS-MS (40 eV) also indicated an [M+H] + at m/z 313 consisting of two
benzoyl moieties with potassium salt as the base peak, correlating to the loss of one hexose (m/z
162).
Compound 1: 6′-O-(3,4-Dihydroxybenzoyl)-4′-O-(4-hydroxybenzoyl)-α/β-D-glucopyranoside
(1), colorless gum; C14H19O9; []D23: 1.85 (c 8.5, MeOH); UV (MeOH) max nm (log ɛ): 261, 221,
203, 189; IR (KBr) max cm-1: 3432, 2923, 1682; ESI-QTOF MS/MS on m/z: 331.28 (40 eV) m/z

(%): 313 (31), 261 (14), 239 (17), 169 (100), 149 (60). The spectra are presented in supplementary
information (Figure S1-S8) and NMR resonances are provided as Table 1.
The 1H NMR spectrum of 1 shows three aromatic protons at δH 7.46 (d, J2, 6 = 1.7 Hz, H-2), 7.42
(dd, J6, 5 = 8.4 Hz, J6, 2 = 2.0 Hz, H-6), and 6.84 (d, J5, 6 = 8.4 Hz, H-5), consistent with a 3,4disubstituted benzoyl moiety. An additional disubstituted aromatic ring proton exhibited an AA′
BB′ pattern. A 2H doublet, resonant at  7.72 (J2″, 3″ = 8.7 Hz, J6″, 5″ = 8.5 Hz), was due to H-2″
and H-6″. Similarly, another 2H doublet at  6.84 (J3″, 2″ = 8.1 Hz, J5″, 6″ = 8.3 Hz) was assigned
to magnetically equivalent H-3″ and H-5″. The coupling constants of 8.7 and 8.5 Hz were
suggestive of their ortho coupling (Table 1). The protons signals at δH 5.32, 3.55, 3.92, 4.27, 4.47,
3.93a, 3.94b are consistent with an α-glucose, while those at δH 4.60, 3.35, 3.53, 3.86, 3.49, 4.57a,
and 5.0b are characteristic for β-glucose moiety, indicating that the compound exists as a mixture
of α- and β-D-glucopyranosides. In both cases, the presence of two downfield resonances in
addition to the anomeric proton suggested the presence of two esters. This association of the spin
systems can be confirmed using COSY.
Table 1: 1H and 13C NMR data for compound 1 in CD3OD.
C. No.
3,4-Dihydroxybenzoyl
C-1
C-2
C-3
C-4
C-5
C-6
C-7
Glucose
C-1'
C-2'
C-3'
C-4'
C-5'
C-6' a/C-6′b

13

C-NMR
(δ)

114.6 / 114.5
115.5 / 115.5
149.2 / 149.1
146.5/ 158.1
111.9 / 111.9
121.4 / 121.4
168.5 / 167.7
94.2 / 98.7
74.3 / 76.6
71.4 / 74.0
64.2 / 68.7
78.2 / 77.6
65.5 / 66.8

H-NMR (δ) (J=Hz)

1

7.46 d (1.7)
6.84 d (8.4)
7.42 dd (8.4, 2.0)
-

Multiplicity

C
CH
C
C
CH
CH
C

5.32 d (3.5) / 4.60 d (8.7)
CH
3.55 dd (7.5, 3.3) / 3.35 dd (7.5, 3.7)
CH
3.92 t (7.7) / 3.53 d (7.9)
CH
4.27 t (8.0) / 3.86 t (8.0)
CH
4.47 t (7.3) / 3.45 dd (7.5, 1.9)
CH
3.93 dd (11.9, 5.4), 3.94 dd (11.9, 5.4) / CH2 a / CH2 b

4.57dd (12.0, 5.0), 5.0 dd (12.0, 5.3)
4-Hydroxybenzoyl
C-1"
C-2"
C-3"
C-4"
C-5"
C-6"
C-7"

110.2 / 110.0
129.7 / 129.5
116.5 / 116.5
148.8
116.5 / 116.5
129.7 / 129.5
169.3 / 168.4

7.72 d (8.7)
6.68 d (8.5)
6.68 d (8.5)
7.72 d (8.7)
-

C
CH
CH
C
CH
CH
C

The 13C-NMR spectrum of compound 1 showed signals for 20 magnetically distinct carbons in the
molecule, but twinned, suggesting two closely related compounds are present. This is typical of a
mixture of anomers for a glycoside formed through a non-enzymatic process. The DEPT spectra
shows one methylene, twelve methine, and seven quaternary carbons. Downfield signals at δppm
146.5, 158.1, and 148.8 were assigned as hydroxylated aromatic carbons. Two substituted aromatic
quaternary carbons were observed at δppm 114.5 and 110.0, while the two downfield quaternary
carbons at δppm 168.4 and 167.7 are clearly ester carbonyl carbons. The other two downfield signals
at δppm 98.8 and 94.2, are typical of acetal carbons at the anomeric centre of reducing-sugar
pyranoside carbohydrates (Table 1). One oxy-methylene carbon appeared upfield at δppm 66.8/65.5
and one of the oxy-methine is also upfield at 68.7/64.2. These are both indicative of ester rather
than ether/alcohol functionalization, suggesting these two carbons, 4’ and 6’, are the locations of
the esters. The other characteristic signals of alcohol or ether-subsittuted α-D-and β-D-sugar
moieties suggested that the compound existed as a diastereomeric mixture of α and β-Dpyranosides with a free anomeric OH [6]. The NMR spectra of compound 1, along with IR and
MS data, further suggests that compound 1 is a dibenzoyl-substituted glucose, where one of the
aryl groups is a para-phenol and the other a 3,4-catechol.
The structure of compound 1 was deduced from a combination of HMQC, HMBC, 1H-1H COSY45º, and 1D-TOCSY NMR experiments. 1D-TOCSY NMR experiments suggested three spin

systems. The benzoyl carbon at 168.5/ 167.7 (C-7) was correlated with the downfield oxymethylene protons (2H-6′) of the sugar unit. Similarly, ester carbonyl C-7″ (169.3/168.4) of the
other benzoyl moiety also exhibited HMBC interactions with the downfield methine H-4′ of sugar
(Figure 2). Additional information about the structure came from the COSY-45o experiment. The
above spectroscopic information strongly suggested that compound 1 is 6′-O-(3,4dihydroxybenzoyl)-4′-O-(4-hydroxybenzoyl)-α/β-D-glucopyranoside. Although ester migration is
possible in carbohydrates, especially under significant processing as was conducted in our
purification, we avoided the basic conditions that facilitate this, and the trans orientation of the
alcohols in glucose does suppress this pathway compared to other sugars with cis-oriented
hydroxyls, so the location of the ester groups is most likely not a figment of the purification.

Figure 1: The structures of compounds (1-5) isolated from the butanol extract of S. molesta.

Figure 2: Key HMBC interactions used to elucidate the structure of compound 1.

3.2. Biological activity analysis
The ChEMBL database was mined to identify the biological activities of compounds with close
structural analogy to 1. Glucose derivatives differentially substituted with two 3,4,5trihydroxybenzoic acid esters have shown anticoagulant, antihypertensive, and anti-HCV
behaviour (CHEMBL518217, CHEMBL458684, and CHEMBL224536). Based on the activities
of the crude butanol extract, and the reported activities of comparable compounds in literature, a
panel of activates was selected to screen the biological potential of 1 (Table 2) [6, 8].

Table 2: Biological activities of compound 1.
Activity
DPPH

% Inhibition
(500 μM)

Standard
inhibitor

88.69

Gallic acid

IC50 (µM)
Mean±SEM
1
Standard
48.24±0.31 23.34±0.43

Superoxide anion radical
93.33
Quercetin
47.25±0.94 95.41±0.98
Oxidative burst
78.54
Ibuprofen
42.12±1.80 25.65±1.90
+2
Fe chelation
-13.33
EDTA
NA
131.00±0.01
Anti-glycation
47.25
Rutin
NA
27.34±0.07
Cytotoxicity (HeLa)
27.12
Doxorubicin
NA
0.20±0.03
Cytotoxicity (PC-3)
36.22
Doxorubicin
NA
0.25±0.008
Carbonic anhydrase-II
-1.6
Acetazolamide
NA
0.12±0.007
Phosphodiesterase-I
99.80
EDTA
337.80±3.50 265.50±0.07
NA = not active in the range of test concentrations.

3.2.1. Antioxidant activities
Oxygen-containing free radicals produced in the living systems disturb redox homeostasis, making
them important in the pathogenesis of various disorders, e.g., cancers, cardiovascular diseases, and
neurodegenerative disorders [36]. The use of antioxidants, usually from a plant source, is a key
strategy to fight against these reactive oxygen species (ROS). The DPPH and superoxide
scavenging assays are standard methods to investigate the antioxidant potential of a compound
3.2.1.1. DPPH radical scavenging activity:
The in vitro DPPH scavenging assay, employing gallic acid as the positive control, revealed that
1 presents potent activity with an IC50 of 48.24±0.31 µM; comparable with gallic acid (IC50 of
23.34±0.43 µM, Table 2).
3.2.1.2. Superoxide anion radical scavenging activity:
The superoxide anion radical (O2-1) is generally formed through the one-electron reduction of
molecular oxygen by the membrane-bound nicotinamide adenine dinucleotide phosphate oxidase
(NADPH oxidase). These can cause significant damage if present in sufficiently high concentrait
Similarly, 1 demonstrates strong superoxide anion radical scavenging capacity with an IC50 of
47.25±0.94 µM, when compared with a standard inhibitor, quercetin (IC50 = 95.41±0.98 µM,
Table 2).

3.2.1.3. Oxidative burst activity using chemiluminescence technique
A whole blood-cell luminol-enhanced chemiluminescence assay, evaluating the oxidative
potential of 1, provided an IC50 of 42.12±1.80 µM compared to the standard ibuprofen (IC50 =
25.65±1.90 µM). This in vitro antioxidant assay is a better model of living systems than either the
DPPH and superoxide assays, and this activity is consistent with moderate action.
The promising antioxidant activities of 1 in the selected assays is likely due to the aromatic
hydroxyl groups, and this behaviour is not surprising for this class of molecule [37].
3.2.1.4. Fe+2 chelation activity:
Employing an in vitro Fe+2 chelation assay, compound 1 was found to be inactive with -13.33%
inhibition at 0.5 mM.
3.2.2. Antiglycation activity:
Compound 1 was inactive in the in vitro HAS-fructose glycation assay, showing an ineffective
47.25% inhibition at 0.5 mM.
3.2.3. Anticancer activity
Compound 1 was investigated for anticancer potential using an MTT assay with HeLa and PC-3
cancer cell lines. The results revealed that this compound is largely nontoxic with 27.12 and
36.22% lethality at 0.5 mM for the two lines respectively after a 48 h incubation.
3.2.4. Phosphodiesterase-I inhibition activity
Nucleotide pyrophosphatases/phosphodiesterases (NPPs, EC 3.1.4.1) are hydrolases of phosphoric
acid diesters, which catalyze nucleoside-5´-monophosphates production from a variety of
pyrophosphates, including nucleoside diphosphates and triphosphates, NAD, FAD, and UDP-

glucose. They also cleave the phosphodiester bonds of oligonucleotides and exogenous substrates
at di-p-nitrophenyl phosphate or the p-nitrophenyl ester of TMP. NPP-1, an essential regulator of
tissue calcification, is mainly located on the cells of the distal convoluted tubule of the kidney,
osteoblasts, epididymis chondrocytes, and hepatocytes. Its Upregulation is positively correlated
with chondrocalcinosis; on the other hand, its downregulation triggers severe periarticular
calcification in mice and idiopathic infantile arterial calcification syndrome in humans [38, 39].
Compound 1 was also assessed for its in vitro phosphodiesterase-I inhibitory potential. This
isolated compound showed a weak inhibition against the phosphodiesterase-I enzyme, with IC50 =
337.80±3.50 µM when compared with the standard inhibitor, i.e., EDTA IC50 = 265.50±0.07 µM.
3.2.5. Carbonic anhydrase-II inhibition activity
Isolate 1 depicted no in vitro carbonic anhydrase-II inhibition potential, as it exhibited -1.6 %
inhibition at 0.5 mM.
3.2.6. Urease inhibition and mechanistic studies
Compound 1 exhibited significant in vitro urease inhibition (Table 3). In our preliminary screen
at 0.5 mM, this compound showed 89% inhibition of urease; concentration experiments suggest
that the IC50 value is 99.1±0.8 µM. We thought that activity could arise from the sequestration of
the nickel present in the enzyme’s active site. To provide some support for this hypothesis, we
conducted a combination experimental and in silico study.

Table 3: The inhibition of compounds 1 against urease and its enzyme kinetics.
Compound
1
Standard (thiourea)

% Inhibition
(0.5 mM)
89.0
98.2

IC50±SEM
(M)
99.1±0.81
21.0±0.11

Ki±SEM
(M)
91.83±0.090
20.0 1±0.02

Type of inhibition
Mixed-type inhibition
Competitive inhibition

Kinetic studies suggested a mixed type of urease inhibition with a Ki value of 91.83±0.09 µM
(Table 3). Lineweaver-Burk plots were used for determining the type of inhibition, wherein the
reciprocal of the rate of reaction was plotted against the reciprocal of the substrate concentration
to monitor the effect of the inhibitor on Km and Vmax (Figure 3A). The Lineweaver-Burk plots
were then used to determine the Ki value (Figure 3B) by plotting the slope of each line in the
Lineweaver-Burk plots as a function of the concentration of 1. The Ki value was validated from
the Dixon plot by plotting the reciprocal reaction rate as a function of the concentration 1. To better
understand this interaction, we explored the binding mode of 1 with urease using in silico
techniques.
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Figure 3: The inhibition of jack bean urease enzyme by compound 1; A is the Lineweaver-Burk
plot of reciprocal of rate of reaction (velocities) versus reciprocal of the substrate (urea) in the
absence (▼), and in the presence of 40 µM (▲), 80 µM (■), 150 µM (●), and 200 µM (○) of
compound 1, B is the secondary replot of the Lineweaver-Burk plot between the slopes of each
line from Lineweaver-Burk plot versus different concentrations of compound 1.

3.3. Molecular docking and simulation
Of all of these proteins, 1 only showed reasonable affinity for the urease. Although we had
hypothesized that the catechol could be chelating to the nickel, none of the low lying conformations
had 1 interacting directly with the nickel atoms. Instead, the carbohydrate positions itself deep
inside the pocket near the metal atoms of the (αβ)8 TIM barrel domain, and projects the two
hydroxylated phenols outwards into the solvent (Figure 4A). The highest docking score
conformation of 1@urease was used as the starting geometry for a 50 ns MD simulation to evaluate
the binding mode stability and the interactions of compound 1 with the urease. The most likely
conformation for 1 was extracted from the MD through clustering analysis [40]. This pose
clustering also eliminates the false positives that arise from molecular docking reducing error [41].
Over the simulation period, the carbohydrate ring remained firmly anchored inside the pocket,
with movement proceeding mainly through the minor vibrations of the solvent-facing benzoyl
groups (Figure 4B). As seen from the root mean square deviation (RMSD) trajectory analysis
(Figure 4C), the ligand-protein complex of compound 1 remained very stable throughout the
simulation period. Similarly, the RMSD trajectory of compound 1 from its initial docked
conformation only experienced minor fluctuations during the pre-MD equilibration (RMSD value
of < 0.5Å), suggesting that the selected docked structure well represents the energetic minimum.
The stable RMSD derives from the strength of the conserved molecular interactions of the ligand
with the active site.

Figure 4: Molecular modeling studies against jack-bean urease. A) Overall structure of jack-bean urease monomer
consisting of four domains: the N-terminal αβ domain (magenta), another αβ domain (red), a β domain (yellow), and
the C-terminal (αβ)8 TIM barrel domain (green). The docked conformation of compound 1 is displayed inside the
active site. (B) The “most-representative” conformation of 1 arising from the MD simulation is magnified to highlight
the key H-bonds. The bi-nickel center is positioned deep inside the active site and does not interact with the ligand.
(C) Root mean square deviation of protein (red) and compound 1 (black) is displayed for a period of 50 ns. (D)
Hydrogen bond occupancy between protein-ligand complex throughout simulation calculated in 12500 snapshots
(after every 4 ps). (E) The total binding free calculations using mmgbsa method, calculated from 1000 snapshots (after
every 50 ps) and the trajectory is displayed.

An in-depth interaction analysis was carried out through H-bond occupancy (distance ≤ 3 Å; angle
≥120°) over a period of 50 ns simulations. The bi-nickel center was found well-positioned as
reported in the crystal structure, coordinated by histidine residues, Ni1 with His492 and His545,

and Ni2 with His407 and His409. The carbohydrate moiety reached deep into the pocket and
established hydrophobic interactions with two essential histidine residues, His519, His545 bearing
the nickel ion, His593, Arg609, Asp494, and Cys592. Here, the hydroxyl group formed H-bond
(48.3%; average distance, 2.65 Å) with the side chain NE2 atom of His492. In phosphate-inhibited
urease of B. pasteurii, the Ni1-bound phosphate oxygen forms an H-bond with His492 [20, 42].
The carbohydrate moiety with its ester linkage occupied most of the volume of the active site and
bound in an orientation where the terminal dihydroxy benzene moiety established two very
consistent H-bonds with the sidechain NE (64.3%; average distance, 2.61 Å) and NH1 (49.8%;
average distance, 2.68 Å) atoms of Arg439. The involvement of the side chain of Arg439 in
establishing H-bonds with other inhibitors has already been reported in several studies [16, 17, 43,
44]. Likewise, the second terminal phenol established a moderate H-bond occupancy (32.8%;
average distance, 2.76 Å) with Ala436.
To better understand the binding free energy of the complex, a more rigorous molecular mechanics
generalized Born surface area (MM/GBSA) method was utilized for binding energy calculations,
which embodies a more physically sound interpretation than docking scoring function [45, 46].
This method is perhaps a promising approach for binding energy estimations and is considered a
more accurate end-point method [35, 46-48]. MM/GBSA methods have been widely used in
protein-ligand biomolecular studies [45, 49] and lead optimization studies [50, 51]. For the MD
simulated complex with the bound compound 1, a total of 1000 snapshots (every 50 ps) were
generated, and the overall trajectory was plotted. Overall, the total binding free energy (ΔGtotal)
was found consistent throughout the simulation (Figure 4E), with an average value of -31.09
kcal/mol. Since, entropic calculations are computationally expensive, only the last 50 frames were
calculated to evaluate the entropic contributions (TΔS) in ligand binding [52], which play a

significant role in predicting accurate ligand binding energy (ΔGbind) [47]. The overall energy
contributions are tabulated in Table 4. The van der Waals (ΔEvdW) interactions majorly contributed
to protein/ligand complex stabilization (-35.7 kcal/mol) as compared to electrostatic contributions
(ΔEele = -21.23 kcal/mol). The solvation effect in the complex (ΔGsol = 25.68 kcal/mol), and
entropic terms (TΔS = 22.9 kcal/mol) account for -8.35 kcal/mol of absolute ΔGbind. To estimate
the rationale of ΔGbind, the Ki was converted to experimental binding free energy (ΔGbind-Ki), and
a quantitative agreement was observed with the experimentally derived value for compound 1.
Table 4: Binding free energy calculations of the protein-ligand complex by MM/GBSA method.
ΔEvdw ΔEele ΔEMM (-)TΔS ΔGp ΔGnp ΔGsol ΔGbind ΔGbindKi
- -56.93 22.9 31.1 -5.47 25.6 -8.35 -5.547
-35.7
21.23
5
8
†
All energies were calculated in kcal/mol. The ΔGbind is calculated using eq. 4, while
ΔGbind while ΔGbind-Ki is experimental binding free energy calculated from IC50 values
calculated by the following equation: ΔGbind-Ki = − RT ln(Ki).
Energy
components†
Compound 1

4. Conclusion
Phytochemical investigation of S. molesta led to the isolation of a new carbohydrate, compound 1.
A panel of biological activities was performed to discover its medicinal potential. Results showed
that it has potent antioxidant activities. Interestingly compound 1 was also found to be a weak
inhibitor of the phosphodiesterase-I enzyme. Additionally, compound 1 showed promising activity
against the urease enzyme, which directed us towards enzyme kinetic and molecular dynamics
simulation studies. The new isolate appeared to be a competitive inhibitor of urease with low
micromolar Ki, suggesting its putative application as a template drug for urease associated diseases,
although the value is not strong enough for it to be prioritized for further development. However,
this molecule needs to be further evaluated through the animal model, i.e., in vivo or tissue culture-

based ex-vivo studies, to establish their therapeutic potential against oxidative stress
phosphodiesterase-II, and urease-induced pathologies.
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